Focus on AVLAYAH launch trajectory: Q3 guidance of $10-12M implies rapid quarter-over-quarter growth, which could drive upside if sustained. However, the DNL151 failure and DNL593 delay remove near-term pipeline catalysts. Monitor the Q3 revenue print and any updates on the DNL126 BLA submission timeline for 2027.
Price Chart
Executive Summary
Denali Therapeutics reported Q2 2026 results with AVLAYAH generating $3.6M in its first full commercial quarter, beating consensus revenue estimates of $2.2M. EPS of -$0.68 missed consensus of -$0.47 due to commercial build costs and lower interest income. Q3 AVLAYAH revenue guidance of $10-12M signals accelerating uptake, partially offsetting the negative pipeline news of the DNL151 (LRRK2) Phase 2b failure and the DNL593 (FTD-GRN) data delay to 2027.
Key Financial Metrics
Key Facts
- AVLAYAH net product revenue of $3.6M in Q2 2026, first full quarter of launch
- Q3 2026 AVLAYAH revenue guidance of $10.0M to $12.0M
- EPS of -$0.68 vs consensus -$0.47 (miss of 44.7%)
- Net loss of $127.6M vs $124.1M in Q2 2025
- Cash, equivalents and marketable securities ~$940M at June 30; pro forma >$1.1B after $195M PRV sale in July
- DNL151 (LRRK2) Phase 2b LUMA study failed; development discontinued in idiopathic Parkinson's
- DNL593 (FTD-GRN) Phase 1/2 data now expected in 2027 (previously end of 2026)
- FDA granted Orphan Drug Designation to DNL593 for FTD-GRN in August 2026
Financial Impact
Revenue beat of $1.4M (63.6%) vs consensus; EPS miss of $0.21 (44.7%) vs consensus; cash strengthened by $195M PRV sale
Risk Factors
- AVLAYAH launch may not sustain momentum if payer coverage or patient starts slow
- DNL151 failure removes a major pipeline asset; DNL593 delay pushes key data out
- Competition from other Hunter syndrome therapies (e.g., Takeda's Elaprase) and emerging BBB-penetrating drugs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001714899-26-000096 |
| Document: dnli-20260806.htm | 0001714899-26-000096 |
| Document: 0001714899-26-000096-index-headers.html | 0001714899-26-000096 |
| Document: 0001714899-26-000096-index.html | 0001714899-26-000096 |
| Document: 0001714899-26-000096.txt | 0001714899-26-000096 |
| 8-K Data (Synthetic) | 0001714899-26-000096 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $21.57 $20.06 | ▼ −7.00% | ▼ −6.34% | $20.00 (−7.28%) |
Sep 4, 2026 27d ago | Insider Cluster | $22.08 $20.38 | ▼ −7.70% | ▼ −6.58% | $20.00 (−9.42%) |
Aug 6, 2026 8w ago | 8-K | $24.83 $24.40 | ▼ −1.73% | ▼ −2.13% | $20.00 (−19.45%) |
Jul 27, 2026 9w ago | Press Release | $24.05 $23.15 | ▲ +3.74% | ▲ +6.01% | $20.00 (+16.84%) |
Jun 18, 2026 15w ago | 8-K | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 18, 2026 15w ago | Press Release | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.02 $23.49 | ▲ +11.75% | ▲ +11.32% | $20.00 (−4.85%) |
May 21, 2026 19w ago | Press Release | $18.64 $20.41 | ▼ −9.50% | ▼ −7.84% | $20.00 (−7.30%) |
May 7, 2026 21w ago | Press Release | $19.62 $19.39 | ▼ −1.17% | ▼ −2.64% | $20.00 (+1.94%) |
Apr 3, 2026 26w ago | 8-K | $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $20.00 (+3.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access